Cargando…

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Ovarian cancer is one of the most lethal gynaecological malignancies worldwide. Despite high success rates following first time treatment, this heterogenous disease is prone to recurrence. Oncogenic activity of receptor tyrosine kinases is believed to drive the progression of ovarian cancer. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rendell, Aimee, Thomas-Bland, Isobel, McCuish, Lee, Taylor, Christopher, Binju, Mudra, Yu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495728/ https://www.ncbi.nlm.nih.gov/pubmed/36140214 http://dx.doi.org/10.3390/biomedicines10092113

Ejemplares similares

Pim kinases in hematological malignancies: where are we now and where are we going?
por: Mondello, Patrizia, et al.
Publicado: (2014)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

A meta-analysis of trends in general, sexual, and violent recidivism among youth with histories of sex offending
por: Lussier, Patrick, et al.
Publicado: (2023)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Personal workstations: Where are we now?
por: Willers, Ian Malcolm
Publicado: (1982)

Personal genomics: Where are we now?
por: Angrist, Misha
Publicado: (2016)

9. GFR - Where are We Now?
por: Delanghe, Joris R.
Publicado: (2009)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Intracranial Atherosclerosis: Where Are We Now?
por: Kim, Jong S.
Publicado: (2017)

Mindfulness in psychiatry – where are we now?
por: Groves, Paramabandhu
Publicado: (2016)

MHC Restriction: Where Are We Now?
por: Zareie, Pirooz, et al.
Publicado: (2020)

Microbiota and Obesity: Where Are We Now?
por: Ballini, Andrea, et al.
Publicado: (2020)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Hepatocellular adenoma: Where are we now?
por: Wang, Xi, et al.
Publicado: (2022)

Osteopontin and Transplantation: Where Are We Now?
por: Kaleta, Beata
Publicado: (2021)

Epilepsy and psychosis– where are we now?
por: Pereira, I., et al.
Publicado: (2021)

Tuberculosis elimination: where are we now?
por: Matteelli, Alberto, et al.
Publicado: (2018)

Crop Improvement: Where Are We Now?
por: Sourdille, Pierre, et al.
Publicado: (2022)

Genetics of migraine: where are we now?
por: Grangeon, Lou, et al.
Publicado: (2023)

Articular Cartilage Repair: Where We Have Been, Where We Are Now, and Where We Are Headed
por: Grande, Daniel A., et al.
Publicado: (2013)

Risk-reducing surgery for breast and ovarian cancer risks - where are we now?
por: Hallowell, N, et al.
Publicado: (2012)

Ovarian cancer in the older patient: where are we now? What to do next?
por: Rousseau, Frédérique, et al.
Publicado: (2023)

Yellow fever control in Cameroon: Where are we now and where are we going?
por: Wiysonge, Charles Shey, et al.
Publicado: (2008)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Structure functions and the EMC effect: where are we now and where are we going to?
por: Wimpenny, S J
Publicado: (1984)

Cardiovascular Tissue Engineering: Where We Come From and Where Are We Now?
por: Smit, Francis E., et al.
Publicado: (2015)

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?
por: AHMED, MOHAMED H
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qogd3t3qsg83dkkcsgk1rqas7n